LM2I, a derivative of Spinosyn A (SPA), serves both as an argininosuccinate synthase (ASS1) enzyme activator and a tumor inhibitor through direct interaction with ASS1. It demonstrates notable antiproliferative effects across seven colorectal cancer cell lines and in colorectal cancer xenograft tumors. Furthermore, LM2I suppresses the growth of colorectal cancer cells by targeting the EGFR pathway [1].